Company Website:
http://www.antibethera.com
TORONTO -- (Business Wire)
Antibe
Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) announced today
that it has completed the process of collecting and reviewing its Phase
I data, further to its January 16, 2015 press release. As a result,
Antibe has resumed the development of ATB-346.
ATB-346’s pharmacokinetic profile, coupled with data on cyclooxygenase
inhibition in humans (an efficacy biomarker) suggests a target
therapeutic dose at or below 250 mg daily, a much lower level than
initially anticipated. It also provides a possible explanation for the
safety issues observed at the 750 mg and 1500 mg doses. At a dose of 250
mg given once daily for 14 days, ATB-346 was safe and well tolerated in
the Phase 1 study.
Accordingly, the Company has concluded its Phase I study and plans to
conduct additional validating studies, prior to continuing with a full
Phase 2 program. The company has made significant reductions in its
overheads and will concentrate its resources on completing the above
studies.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer non-steroidal
anti-inflammatory drug (NSAID) for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a safer analgesic for severe acute pain.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Important
Note on Forward Looking Statements
Contacts:
Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief
Executive Officer
dan.legault@antibethera.com
Source: Antibe Therapeutics Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.